Compare NMI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMI | ANIX |
|---|---|---|
| Founded | N/A | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 114.0M |
| IPO Year | 1995 | 2013 |
| Metric | NMI | ANIX |
|---|---|---|
| Price | $9.60 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 32.2K | ★ 352.7K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.57 | $2.32 |
| 52 Week High | $11.28 | $5.46 |
| Indicator | NMI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 29.60 | 38.62 |
| Support Level | $9.57 | $2.66 |
| Resistance Level | $10.31 | $3.09 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 17.05 | 31.25 |
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.